BIOHAL Open Network ICO

JOIN OUR ICO!

Accelerating Biotech Breakthroughs with PROTEO

Super-Early Detection Liquid Biopsy "PROTEO" for people.
The Biometrics authentication on blockchain changes the world.

Contribute to BIOHAL

  • BTC

  • ETH

  • XRP

  • ADA

Join our Crowd-Sale 2nd

JOIN ICO

News

2018/12/07 For BIOHAL investors, 2nd Crowdsale has been extended.

the BIOHAL OPEN NETWORK

Bio Authentication protocol
BIOHAL OPEN NETWORK is a decentralized preventive medicine platform with liquid biopsy authentication protocol that enables secure and transparent exchange and usage of a variety of medical data.

OUR MISSION

As liquid biopsy experts, we are having an extremely difficult time to know the fact that most people recognized their cancer at stage 1 to 4, needed an emergency surgery or already cannot be cured.
Our mission is to eliminate that situation and find their disease at stage 0.

Standardize and enable comprehensive medical data to authentication to access over the blockchain.

Decentralize the access layer and automate secure authentication for users

Increase the survival rate and Quality of life by early detection system

Enable people around the world to take free liquid biopsy test and overcome their potential diseases.

Capable Solution

BIOHAL OPEN NETWORK is a free, open-source, blockchain based biometrics authentication protocol featuring the reliable and secure architecture of Biometrics: Smart contracts that utilize liquid biopsy test as known as PROTEO.

Decrease Medical Cost
Expand the choice of treatment
Less Burden
No Regional disparities
Full Control liquid biopsy data over blockchain

HOW TO ACTUALIZE GLOBAL TESTING SERVICES?

Our dried serum technology solves!

There are international regulations on every means of transportation of infectious substances (air, rail, road and marine transport as well as mail). The UN model rules are reflected in the international laws through the international model agreements.
We have invented the dried serum technology by separating serum from the blood as a way to solve these problems.
This enables safe transport of dried serum.
By enabling transport of dried serum, it is possible to perform a stable test
whose accuracy is not adversely affected by the condition of transportation.

Focused on Dapp with Liquid Biopsy

BIOHAL OPEN NETWORK is a Biotech Decentralized Solution, Powered by Blockchain & PON Tokens

BIOHAL OPEN NETWORK by design is a platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients).

Accuracy
September 2018
Nearly 100%. We are developing a new system and getting improved.

COMPARISON WITH OTHER SERVICES

BIOHAL is a competitive blockchain platform and the quality of being scalable.

Focused on working with DApp
Bio Authentication Protocol
Artificial Intelligence
Liquid Biopsy Product
Disease Early Detection
Secured health records

BIOHAL OPEN NETWORK use cases

Proof of research

The Data stored in the public blockchain BIOHAL OPEN NETWORK will be the basis of the evidence base.

Protected research

The ability to “scientific research” in a secure format using encrypted key in blockchain ecosystem

Big Data

Global access to the accumulated array of information through an open API interface with the functionality required to analyze the available data.

Ecosystem

A single blockchain platform for collecting, storing and analyzing information methods of diagnosis and treatment of cancer

Smart Blockchain

The possibility of connecting an AI to search for “patterns” for developing new methods of cancer treatment

PON Tokens

Usage through interaction within the ecosystem of patients, researchers, Regulator, CRO, pharmaceutical companies, clinics

BIOHAL OPEN NETWORK Ecosystem

community roles

General Users(Patients)

Medical Doctors

Clinics

Pharmaceutical companies

Insurance companies

Sponsors / Investors

National Ethical Committees

Researchers

Contract research organizations (CRO)

Experts

Regulators

Big Data

Enter the Precision Medicine Market with BIOHAL OPEN NETWORK

Innovative Precision Medicine and Blockchain technology company specializing in the development of liqud biopsy for early diagnosis of cancer and monitoring the efficacy of cancer treatment

PROTEO Cancer Test
first in the world early stage cancer test with UNPRECEDENTED accuracy!

BIOHAL OPEN NETWORK Whitepaper

What is PROTEO

PROTEO is a liquid biopsy developed and ready.

PROTEO is the liquid biopsy technology which can theoretically detect the very early cancer of approx. 1 mm, and it has obtained an international patent for measuring a nucleosome. PROTEO has been successful in detecting molecular-level cancerモ for the first time in the world.
This is the only test method that can quantify the amount of cancer-related substances.
This is the only test method that can conduct cancer examination for a wide range of age from the infant (childhood cancer) to the elderly.
Samples can be sent to the medical laboratory via international mail; therefore, the area the international mail covers is the target area for this test. This means that its potential demand can be the whole worldユs population of 7.6 billion people.

Very early detection of cancer
from stage 0 (treatment is effective).

Minimally invasive
(very little physical distress).

No medical radiation exposure (safe for those who are pregnant or with possibility of pregnancy).

No fasting or diet restriction required before the test. (can be tested any time)

Blood sample taken at home with self-testing kit (can eliminate disparities in quality of health care).

If a test method that can quantitatively and quickly detect cancer-related or Alzheimer-related substances from blood components is developed, it can contribute not only to treatmentof cancer and Alzheimer but also greatly to reduction of medical expense worldwide.

As PROTEO is known as being applied not only cancer, but also other diseases such as Alzheimer dementia, Arthritis, and so on, PROTEO technology is the key role on this Open network.

RESEARCH PAPER REFERENCE

The technology of PROTEO has been successful in basic research and clinical trials, and the results have been published, including the following.

COMPARISON WITH OTHER SERVICES

Liquid biopsy is ideal as it is minimally invasive; however, it has not been implemented for practical use despite the fact that it has been known as cancer markers in the research publications of exosomes, circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA).

These marker substances begin to be inactivated as soon as they are taken out of blood. It is also unsuitable for quantitative detection since it is terribly difficult to directly extract the target substance only because the available amount in the blood is extremely small. Moreover, it has been kept away from practical use since the protocol up to the detection is complex and requires a long period of time.

MARKET CAPABILITY

Cancer early detection by the liquid biopsy is attracting more attention than ever.
According to a marketing research company, the market size is rapidly growing and estimated in the size of 10 billion US dollars annually.
Piper Jaffray companies, an investment bank reports that field by liquid biopsy is already being developed by 38 companies.
Analysts predicted the market size of the genetic screening by liquid biopsy will be from 20 billion to 40 billion US dollars in USA.

1B

Cancer annually globally

1,000s

Thousands of
biotech Researchers

40M

PROTEO Tests only
in Japan

$150B+

M&A deals on medical market
during each of the last 3 years

PON token sale

PON owners have the following opportunities

•Become a provider of resources in order to provide the data-storage needs of the service, and receive rewards for it.
•To lease out the token to the supplier and receive part of its rewards for using your token.
•To sell the token freely on the stock exchange at market value.

Token detail

Pre-ICO Price

1 PON = 0.06 USD

Price

1 PON = 0.10 USD

Platform

Ethereum

Accepting

ETH, BTC, XRP

Hard cap

550,000,000 USD

Roadmap

2018 - 2023

Phase01

  • 1st Quater, 2018

    Started decentralized medical blockchain project

  • 2nd Quater, 2018

    Started to develop Demo app with Bio medical protocol

Phase02

  • 3rd Quater, 2018

    BIOHAL ICO Launched

  • 3rd Quater, 2018

    Bio Authentication Dapp(β)

Phase03

  • 2nd Quater, 2019

    Establish the new Liquid Biopsy Labs

  • 2nd Quater, 2019

    Release BIOHAL Open Network α

Adviser

Free Template by uiCookies

CEO and Founder
Free Template by uiCookies
Medical Advisor/M.D./Ph.D./Bio Technical Officer
Free Template by uiCookies
Medical Advisor/M.D./Ph.D./Bio Technical Officer
Free Template by uiCookies
CTO/Medical Advisor/M.D./
Bio Technical Officer
Chikamoto
Healthcare Medical Advisor
Bio Technical Officer
Raj

Legal Advisor

Partners

Media

PROTEO liquid biopsy Cancer test is already available in Japan at our first center!

10 PON Tokens to get ahead of millions – sign up for testing at https://www.biohal.io

Documents

Message from CEO
Market
Introduction of PROTEO